Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Lingyu Zeng
Potent Anti-Leukemia Activities of Humanized CD19-targeted CAR-T Cells in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
American Journal of Hematology
Hematology
Related publications
Efficacy and Safety of Humanized Anti-Cd19-Car-T Therapy Following Intensive Lymphodepleting Chemotherapy for Refractory/Relapsed B Acute Lymphoblastic Leukaemia
British Journal of Haematology
Hematology
Locally Produced CD19 CAR T Cells Leading to Clinical Remissions in Medullary and Extramedullary Relapsed Acute Lymphoblastic Leukemia
American Journal of Hematology
Hematology
CAR T Cells for Acute Lymphoblastic Leukemia
American Journal of Hematology
Hematology
CTL019 (Tisagenlecleucel): CAR-T Therapy for Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
CAR-T Cells and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Immunotherapy
Oncology
Allergy
Immunology
Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia
Frontiers in Pediatrics
Child Health
Pediatrics
Perinatology
Outcome of Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia After Blinatumomab Failure: No Change in the Level of CD19 Expression
American Journal of Hematology
Hematology
Shortening the Ex Vivo Culture of CD19‐specific CAR T‐cells Retains Potent Efficacy Against Acute Lymphoblastic Leukemia Without CRES or Severe CRS
American Journal of Hematology
Hematology
In Vitro Cellular Drug Resistance in Children With Relapsed/Refractory Acute Lymphoblastic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
